|
|
Statement of Need/Program Overview
The progression of new therapies for patients with chronic myeloid leukemia (CML)
from the bench to bedside has been rapid, in parallel with the swift advances in
molecular biology. The impact of molecular biology on the diagnosis, monitoring,
and treatment strategies for CML has also been substantial. Although community clinicians
have access to a number of CME/CE activities regarding available treatments and
the associated clinical data, a need remains for education regarding the correlation
of molecular response with the well-understood hematologic and cytogenetic response.
Community clinicians need to understand molecular response, its association with
residual disease, how it is measured, and the interpretation and application of
molecular tests.
Although the technologies, facilities, and educators to address these issues are
readily available at most academic medical centers, they are not within reach of
most community oncologists and their staffs. Utilizing a true workshop format, these
regional meetings will combine the presentation of actual clinical situations (illustrated
by the faculty presenter) with an in-depth inquiry and interactive discussion related
to critical decisions. Finally, community clinicians—physicians, nurses, nurse practitioners,
and physician assistants—will have access to the hands-on education they need regarding
the basis for and evidence supporting recent guidelines and recommendations concerning
the monitoring of molecular response to available therapies.
Target Audience
Hematologists, hematologist/oncologists, medical oncologists, oncology nurses, nurse
practitioners, and physician assistants who treat patients with chronic myeloid
leukemia
Learning Objectives
- You will assess the methodologies used for monitoring response and evaluate the
relationship between cytogenetic response, molecular response, and residual disease.
- You will evaluate the prognostic significance of the timing, depth, and stability
of molecular response and be better able to use molecular monitoring results in
guiding management decisions.
- You will be able to explain molecular response results in relation to the development
of resistance-conferring mutations and disease progression, validating the role
of frequent molecular testing in guiding management decisions.
- In light of updated recommendations and guidelines, you will be able to implement
frequent molecular monitoring into your practice.
Accreditation/Designation of Credit Statements
Veritas Institute for Medical Education, Inc. is accredited by the Accreditation
Council for Continuing Medical Education to provide continuing medical education
for physicians.
Veritas Institute for Medical Education, Inc. designates this educational activity
for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians
should only claim credit commensurate with the extent of their participation in
the activity.
Nurse Practitioners
Veritas Institute for Medical Education, Inc. approved as a provider for nurse practitioner
continuing education by the American Academy of Nurse Practitioners: AANP Provider
Number 040309. This program has been approved for 2.0 contact hours of continuing
education (which includes 2.0 hours of pharmacology).
Nurses
Veritas Institute for Medical Education, Inc. approved by the California Board of
Registered Nursing, Provider #13986 for 2.0 Contact Hours.
Financial and Off-Label/Investigational Uses of Drugs/Disclosure Statement
The relevant financial relationships of those persons in a position to control the
content of this CME activity will be disclosed prior to the start of the educational
activity. Participants are advised that this CME activity will contain references
to unlabeled/unapproved/investigational uses of drugs to treat patients with CML.
Sponsorship and Support
Sponsored by Veritas Institute for Medical Education, Inc.
Supported by educational grants from Bristol-Myers Squibb and Novartis Oncology,
with additional support from MolecularMD.
|